CELC Celcuity (CELC) Q4 FY25 earnings call
Celcuity concluded fiscal year 2025 with significant clinical and regulatory advancements for gedatolisib, including FDA priority review for its NDA in HR-positive/HER2-negative advanced breast cancer, supported by strong VIKTORIA-1 wild-type data. The company is actively preparing for commercial launch, building out its sales force and engaging payers, while also anticipating key mutant cohort trial results and exploring further indications. The financial results reflect increased R&D and G&A expenses as the company nears potential commercialization.
You’re reading a preview. Opening the full call uses 1 concall credit.
Sign in to use your monthly call allowance.
Inve summary of the company's earnings call; see how call summaries are prepared. Not investment advice.